Search Results
Your search for ,aLl matches 18309 pages
Showing 851 - 900Ablative Radiation Therapy for Resectable Pancreatic Ductal Adenocarcinoma
Ablative radiation therapy is considered to be an alternative to surgery, providing an effective noninvasive option for local treatment of many types of cancer, but it is unknown whether ablative radiation therapy is effective for pancreatic ductal adenocarcinoma. Surgery provides improved...
Rakesh K. Jain, PhD, FAACR, Honored With 2025 AACR Award for Lifetime Achievement in Cancer Research
The 2025 AACR Award for Lifetime Achievement in Cancer Research was presented to Rakesh K. Jain, PhD, FAACR, during the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago. This award honors individuals who have made significant fundamental contributions to cancer...
ASH Studies Bolster Support for Menin Inhibitor in Acute Leukemia
The recent approval of the oral menin inhibitor revumenib brought much-needed treatment to patients with a challenging subset of disease: adults and children with relapsed or refractory acute leukemia harboring a lysine methyltransferase 2A gene (KMT2A) translocation or rearrangement. Approval was...
Joint Clinical Practice Guideline Addresses Opioid Conversion for Patients With Cancer
Several medical organizations recently released a joint Clinical Practice Guideline to provide recommendations on opioid conversion in adults with cancer.1 ASCO, together with the Multinational Association of Supportive Care in Cancer (MASCC), American Academy of Hospice and Palliative Medicine,...
2024 Annual Report to the Nation on the Status of Cancer Finds Mortality Rates Continue to Decline
Overall deaths from cancer over the past 2 decades have steadily declined in both men and women in the United States, according to the 2024 Annual Report to the Nation on the Status of Cancer, which was published by Recinda L. Sherman, MPH, PhD, ODS-C, of the North American Association of Central...
Off-the-Shelf Natural Killer CAR T-Cell Therapy Shows Efficacy in Small Study of Relapsed or Refractory Blood Cancers
The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor (CAR) T-cell therapy in 2017 to treat children with acute lymphoblastic leukemia.1 Over the past decade, other CAR T-cell therapies have been FDA approved to treat adults with blood cancers, including...
Evolving Role of Surgical De-escalation for Endometrial, Ovarian, Cervical, and Vulvar Cancers
For more than a decade, the field of gynecologic oncology has witnessed a movement toward surgical de-escalation through the increased use of minimally invasive surgical techniques and sentinel lymph node techniques. At the 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s...
Study Shows Disparities in Diagnosing Endometrial Cancer in Women With Postmenopausal Bleeding
Angela Nolin, MD, a gynecologic oncology fellow at Duke University Health System in Durham, North Carolina, and colleagues conducted a multi-institutional study to determine whether racial differences in transvaginal ultrasound efficacy combined with timely receipt of indicated endometrial...
Quick Takes on Research Findings on Novel Therapies for Gynecologic Cancers
The 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer advanced the field with updates of practice-changing trials and other research that challenges the conventional approaches to treating gynecologic cancers. We have briefly captured some of that research here for readers ...
Symptoms Preceding Unplanned Acute Care in Patients With Cancer
In a single-institution cohort study reported in JAMA Network Open, Chang et al identified patterns of symptoms preceding unplanned acute care encounters for patients with cancer. Study Details The study involved data from all unplanned acute care encounters (emergency department visits and...
HIV-Related Structural Barriers in Cancer Care
Patients with human immunodeficiency virus (HIV) are less likely to receive potentially life-saving cancer treatment if they reside in communities with lower income levels and educational attainment, according to a recent study published by Islam et al in Cancer. Study Methods and Results...
Influence of ACA on Breast Reconstruction Disparities
Despite steady increases in the rates of immediate postmastectomy breast reconstruction, racial disparities in receipt of the procedure have persisted in the years since the implementation of the Affordable Care Act (ACA), according to a recent study published by Schafer et al in Plastic and...
Five Major Advances in Radiotherapy for Anal and Rectal Cancer Presented at ESTRO 2025
Five pivotal studies presented at ESTRO 2025 showcase how radiotherapy is reshaping the landscape for anal and rectal cancers. From reduced-dose treatments to cutting-edge combinations with immunotherapy and chemotherapy, these innovations offer safer, more effective, and organ-preserving...
New Treatment Approach Could Enhance Care for Aggressive Relapsed/Refractory T- and NK-Cell Lymphomas
Investigators have uncovered how a specific sequence of cancer therapies could improve outcomes among patients with relapsed/refractory mature T- and natural killer (NK)-cell lymphomas, according to a recent study published by Sorial et al in the British Journal of Haematology. Background...
Cancer Briefs From Digestive Disease Week 2025
Cancer-related studies were among the nearly 6,000 abstracts presented at Digestive Disease Week® (DDW) 2025, including research on artificial intelligence (AI) in patient communication, polyp detection, and colonoscopy prep. Use of AI in Patient Communication AI outperformed physicians in...
Anal Cancer Rates Rising Most Among Older White and Hispanic Women
Anal cancer has been steadily increasing in the United States, with the biggest jumps among older women, especially White and Hispanic women, a new study presented at Digestive Disease Week 2025 (Abstract 76) found. According to the investigators, this shift challenges assumptions about high-risk...
Financial Toxicity Tumor Board: Can It Reduce Treatment Costs?
The Atrium Health Levine Cancer Institute established a Financial Toxicity Tumor Board in 2019. The board is the first known institutional-level intervention of its kind and functions like a traditional disease-focused multidisciplinary tumor board—with a singular focus on financial distress. Now,...
AML: MRD Testing Led to Survival Benefits in Subset of Patients
Sequential molecular measurable residual disease (MRD) testing and monitoring led to a survival benefit among younger patients with acute myeloid leukemia (AML) and NPM1 and FLT3-ITD mutations, according to the results of a study published in The Lancet Haematology. Patients with both mutations...
Addition of Perioperative Pembrolizumab to Standard of Care in Newly Diagnosed Locally Advanced Head and Neck Cancer
In the phase III KEYNOTE-689 trial, perioperative use of the PD-1 inhibitor pembrolizumab given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated patients with locally advanced head and neck squamous cell carcinoma, researchers reported at the ...
Dose Escalation of Fluorodeoxyglucose PET–Guided Radiotherapy for Locally Advanced NSCLC
In an analysis from the Scandinavian phase III NARLAL2 trial, reported in the Journal of Clinical Oncology, Schytte et al found that fluorodeoxyglucose (FDG)-PET–guided heterogeneously dose-escalated radiotherapy was not associated with greater 6-month toxicity vs standard radiotherapy in...
Cannabis Use Disorder Significantly Increases Mortality Risk in Colorectal Cancer
Patients with colorectal cancer and a history of cannabis use disorder had a more than 20 times higher risk of mortality within 5 years than those without cannabis use order, according to the results of a study published in Annals of Epidemiology. The 5-year mortality rate in patients with a...
2025 ACS Cancer Prevention, Early Detection Report: Cancer Screening Rates, Modifiable Risk Factors
Investigators have uncovered mixed progress in major cancer risk factors, preventive behaviors, and screenings in the post–COVID-19 pandemic period among adults in the United States, according to a new study published by Bandi et al in Cancer Epidemiology, Biomarkers & Prevention. Background An ...
Venetoclax-Based Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia
“Knowledge is like a lion; it cannot be gently embraced.” –South African Proverb Long-term efficacy and safety confirm that a hypomethylating agent and venetoclax is an improvement in the standard of care for patients with AML who are not eligible for intensive chemotherapy because of advanced age...
DDW 2025: 20-Year Screening Program Drives Down Colorectal Cancer Cases, Deaths
A 20-year initiative that offered flexible options for colorectal cancer screening at a major integrated health system doubled colorectal cancer screening rates, cut cancer incidence by a third, halved deaths, and brought racial differences in outcomes to nearly zero, according to a study that will ...
DDW 2025: Genetic Mutations Linked to Worse Stomach Cancer Outcomes
Using next-generation DNA sequencing, researchers have identified four specific genes whose mutations are linked to the development and progression of lethal stomach cancers. This could potentially enable practitioners to offer targeted treatments that would spare many patients from unnecessarily...
AACR 2025: Using Single-Cell RNA Sequencing to Evaluate Cell States in AML
A new gene-expression atlas developed using single-cell RNA sequencing data sheds light on how normal hematopoietic cells differentiate and was used to catalog the multiple ways aberrant differentiation can lead to acute myeloid leukemia (AML). Andy G.X. Zeng, PhD, an MD/PhD candidate at the...
AACR 2025: Molecularly Selected, Tumor-Agnostic Phase II Trial Focuses on Combination Therapy
According to the results of a molecularly matched, tumor-agnostic phase II trial, the combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab demonstrated antitumor activity with no new safety signals, particularly in patients with BRCA1/2 mutations. Data from this...
AACR 2025: Trends in Breast Cancer Incidence for Women Between the Ages of 20 and 49
Breast cancer deaths among women between the ages of 20 and 49 declined significantly across all breast cancer subtypes and racial/ethnic groups from 2010 to 2020, with marked declines starting after 2016, according to an analysis of data from the Surveillance, Epidemiology, and End Results (SEER)...
AACR 2025: Pretrained AI Models Could Help Accurately Diagnose Nonmelanoma Skin Cancers in Resource-Limited Settings
Artificial intelligence (AI) models pretrained on vast data sets may outperform standard baseline models in identifying nonmelanoma skin cancers from digital images of tissue samples, according to new findings presented by Song et al at the 2025 American Association for Cancer Research (AACR)...
AACR 2025: Novel Targeted Therapy Under Study in Selected Patients With Advanced Solid Tumors
The first-in-class covalent Werner helicase inhibitor (RO7589831) demonstrated early signals of efficacy as well as general tolerability in patients with advanced solid tumors harboring certain genetic defects, according to results from a phase I trial. Agents in this class target the DNA repair...
AACR 2025: Oral HER2-Targeted Therapy for Advanced HER2-Mutated Lung Cancer
The novel HER2-targeted tyrosine kinase inhibitor zongertinib elicited durable responses in patients with advanced, previously treated non–small cell lung cancer (NSCLC) that harbored a HER2 mutation, according to the preliminary results of the early-phase Beamion LUNG-1 trial. These findings were...
AACR 2025: Off-the-Shelf Natural Killer CAR Therapy Active in Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor (CAR) T-cell therapy in 2017 to treat children with acute lymphoblastic leukemia. Over the past decade, other CAR T-cell therapies have been FDA-approved to treat adults with blood cancers, including...
AACR 2025: Zoldonrasib May Elicit Objective Responses in Patients With KRAS G12D–Mutated NSCLC
The oral KRAS G12D inhibitor zoldonrasib could provide clinical benefit in patients with previously treated non–small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation, according to new findings presented by Arbour et al at the 2025 American Association for Cancer Research (AACR)...
AACR 2025: Use of ctDNA-Based Liquid Biopsy Assay in Resectable Colorectal Cancer
Interim results from the VICTORI study showed that an ultrasensitive circulating tumor DNA (ctDNA)-based liquid biopsy assay was effective in detecting signs of cancer recurrence prior to imaging and provided prognostic value within 1 month after surgery in patients with colorectal cancer. The...
Addition of Neoadjuvant/Adjuvant Pembrolizumab Significantly Improves Outcomes in Locally Advanced HNSCC
The addition of neoadjuvant and adjuvant pembrolizumab to standard-of-care therapy significantly improved event-free survival over the standard of care alone for patients with locally advanced head and neck cancer in the phase III KEYNOTE-689 trial, according to results presented at the American...
Omission of Endocrine Therapy in Estrogen Receptor–Low, Early-Stage Breast Cancer
In a study reported in the Journal of Clinical Oncology, Choong et al found that omission of endocrine therapy in patients with estrogen receptor–low (1%–10% on immunohistochemistry), early-stage breast cancer was not associated with improved survival outcomes. The study used National Cancer...
Childhood Exposure to Bacterial Toxin May Trigger Early-Onset Colorectal Cancer
Researchers may have identified the bacterial toxin colibactin as a potential factor contributing to the concerning rise in early-onset colorectal cancer, according to a novel study published by Díaz-Gay et al in Nature. The findings demonstrated a substantial enrichment of colibactin-related...
Use of Statins in CLL/SLL
Statin use during targeted therapy treatment led to a 61% improvement in the risk of dying of cancer for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to the results of a study published in Blood Advances. The investigators sought to determine the...
Executive Orders and Cancer Care
The Association for Clinical Oncology (ASCO) is working to understand the extent and scope of several recent executive actions. ASCO recognizes the concern and confusion many are currently experiencing and understands that if there are interruptions in care and research, there can be negative...
ASCO Updates Guideline for Fertility Preservation in People With Cancer
ASCO has released an update to the guideline for fertility preservation in people with cancer. The update, recently published in the Journal of Clinical Oncology,1 provides recommendations regarding evaluation and counseling for fertility preservation; methods and timing of fertility preservation;...
Karen E. Knudsen, MBA, PhD, Appointed Chief Executive Officer of the Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy (PICI) announced the appointment of Karen E. Knudsen, MBA, PhD, as its new Chief Executive Officer (CEO). A visionary leader in oncology, health-care delivery, scientific innovation, and strategic transformation, Dr. Knudsen joins PICI at a pivotal time ...
Use of Investigational Tool to Detect Advanced-Stage Invasive Cervical Cancer
At the 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, Kersten Rothnie, MBBS, a gynecologic oncology fellow at Northwell Health in New York City, shared study findings on an investigational tool on behalf of her colleagues.1 These results suggested the presence of...
SGO’s President-Elect Brings Professional Experience and Passion to Her New Role
Society of Gynecologic Oncology (SGO) President-Elect Karen Lu, MD, assumed her official duties on March 17, 2025. Dr. Lu, who is also Executive Vice President and Physician-in-Chief at Moffitt Cancer Center in Tampa, Florida, brings many years of professional experience and active SGO membership...
Hyperefficient and Super-Digitized Health Care: Where Is the Smile?
A few weeks ago, a family member underwent a minor outpatient operative procedure. From a few weeks before the scheduled date of the procedure, multiple text messages and e-mails were forwarded to provide preparatory instructions for the procedure. The day before the procedure, another...
Several Trials Show Clinical Activity With Osimertinib in Advanced EGFR-Mutant Non–Small Cell Lung Cancer
Updates from several clinical trials of the EGFR tyrosine kinase inhibitor osimertinib across stages and settings of EGFR-mutated non–small cell lung cancer (NSCLC) were presented at the European Lung Cancer Congress (ELCC) 2025. The updated results from the phase III LAURA trial were presented by ...
Is This the End of Cancer Research as We Know It?
Ongoing efforts to rein in government spending have been described as a “chainsaw for bureaucracy.” It’s an apt metaphor for the haphazard budget cuts that many federal agencies are still experiencing. On February 7, 2025, the chainsaw made its way to facilities and administrative (F&A)...
Polygenic Risk Score for Prostate Cancer Screening
In a U.K. study (BARCODE1) reported in The New England Journal of Medicine, McHugh et al found that screening for prostate cancer with a polygenic risk score was more accurate in diagnosis than screening with prostate-specific antigen (PSA) and magnetic resonance imaging (MRI). Study Details In...
Benefits of Walnut Consumption: Curbing Inflammation, Colorectal Cancer Risk
Researchers have uncovered that eating walnuts may improve systemic inflammation and reduce the risk for colorectal cancer, according to a recent study published by Moussa et al in Cancer Prevention Research. Background Ellagitannins—plant-derived polyphenol compounds found in walnuts—have been...
Addition of Daratumumab to Treatment Regimen in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma
As reported in The Lancet Oncology by Mateos et al, the final results of the phase III ALCYONE trial showed persistent benefit with the addition of daratumumab to bortezomib, melphalan, and prednisone (D-VMP) in transplant-ineligible patients with newly diagnosed multiple myeloma. The primary...
Response to Immune Checkpoint Inhibitors Not Affected by Age
Older patients with a solid tumor responded with similar clinical outcomes to younger patients treated with immune checkpoint inhibitors, the results of a study published in Nature Communications showed. However, older patients did have divergent immune phenotypes compared with younger patients,...
